MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Arvinas Inc

Cerrado

SectorSanidad

7.17 2.43

Resumen

Variación precio

24h

Actual

Mínimo

6.76

Máximo

7.33

Métricas clave

By Trading Economics

Ingresos

4.1M

-45M

Ventas

-43M

59M

BPA

-0.63

Margen de beneficios

-76.182

Empleados

430

EBITDA

3.7M

-57M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+381.65% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

522M

Apertura anterior

4.74

Cierre anterior

7.17

Noticias sobre sentimiento de mercado

By Acuity

7%

93%

3 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Arvinas Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

11 abr 2024, 11:42 UTC

Adquisiciones, fusiones, absorciones

Arvinas, Novartis in ARV-766 Prostate Cancer License Pact

Comparación entre iguales

Cambio de precio

Arvinas Inc previsión

Precio Objetivo

By TipRanks

381.65% repunte

Estimación a 12 Meses

Media 33.86 USD  381.65%

Máximo 81 USD

Mínimo 10 USD

De acuerdo con 17 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arvinas Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

17 ratings

12

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

7.02 / 8.13Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

3 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arvinas Inc

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.